Opinion

Video

CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease

Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.

Video content above is prompted by the following questions:

  • Describe the use of CSF and blood-based biomarkers in AD.
    • Which biomarkers/histopathological features are associated with different stages of Alzheimer’s disease?
    • What are you using in your practice?
      • What are the unmet needs?
Related Videos
Howard Fillit, MD
Gil Rabinovici, MD
Henri Ford, MD, MHA
Gil Rabinovici, MD
© 2024 MJH Life Sciences

All rights reserved.